



Passion for Innovation.  
Compassion for Patients.™

## Company Timeline and Milestones

2004

Daiichi establishes Daiichi Medical Research, Inc. in Madison, NJ

1990

Daiichi establishes its Development Office in London, UK

1989

Daiichi establishes Sanofi-Daiichi Pharmaceutical Co., Ltd., for the purpose of the medical development of thrombotic disease in Tokyo, Japan

1989

Daiichi establishes Laboratoires Daiichi Sanofi in Paris, France

1980's

Daiichi researchers discover Factor Xa small molecule DX-9065a, becoming the first company to test Factor X as in humans

1980

Daiichi Pharmaceutical Corporation establishes its U.S. Representative Office in New York, NY

1918

Daiichi Pharmaceutical Co., Ltd. is established in Tokyo, Japan

1918

Seinosuke Shibata is appointed as the company's first president

2011

2011

Daiichi Sankyo Group acquires Plexikon and enters U.S. cancer market

Daiichi Sankyo, Inc. acquires first U.S.-based Packaging and Manufacturing Facility, located in Pennsylvania

2009

2009

Daiichi Sankyo, Inc. expands headquarters facility to accommodate its growing workforce

2006

Sankyo Pharma, Inc. and Daiichi Pharmaceutical Corporation integrate to form Daiichi Sankyo, Inc. in Parsippany, NJ

2005

2005

Daiichi and Sankyo close the deal establishing Daiichi Sankyo Co., Ltd. in Tokyo, Japan

2001

2001

Sankyo buys out Sankyo Parke Davis, combining all U.S. commercial operations and R&D into one organization, Sankyo Pharma, Inc.

Sankyo Pharma establishes independent operations in Parsippany, NJ

1998

1998

Sankyo establishes the Sankyo Pharma Research Institute in San Diego, CA

1996

Sankyo and Warner-Lambert set up Sankyo Parke Davis, a U.S. joint venture in New Jersey

1990s

Daiichi scientists develop irinotecan, which is used in cancer therapy.

1989

1990

Sankyo acquires Luitpold Werk GmbH (currently Daiichi Sankyo Europe GmbH)

1985

1985

Sankyo establishes Sankyo USA Corporation, a clinical research organization in New York, NY

Sankyo establishes Sankyo Europe GmbH in Dusseldorf, Germany

1980

1983

Sankyo researcher discovers troglitazone, an insulin sensitizer, marking the origination of the glitazone class

1971

1971

Sankyo researchers discover the first HMG-CoA reductase inhibitor, marking the origination of the statin class

1961

1961

Sankyo establishes a liaison office in New York, NY

1918

1913

Sankyo Co., Ltd. is established in Tokyo, Japan and Dr. Jokichi Takamine is appointed as the company's first president

1912

Dr. Jokichi Takamine orchestrates the gift of 3,000 cherry trees from Tokyo's mayor to Washington, D.C.

1910

1910

Dr. Umetaro Suzuki is the first to discover vitamin B1, establishing the basis for the theory of vitamins

1900

Dr. Jokichi Takamine is the first to isolate epinephrine

1899

1899

Sankyo Shoten, Sankyo's predecessor company, established in Tokyo, Japan